A detailed history of Advisor Group Holdings, Inc. transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 507 shares of MCRB stock, worth $365. This represents 0.0% of its overall portfolio holdings.

Number of Shares
507
Previous 400,493 99.87%
Holding current value
$365
Previous $560,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.75 - $1.56 $299,989 - $623,978
-399,986 Reduced 99.87%
507 $0
Q4 2023

Feb 12, 2024

BUY
$0.93 - $2.15 $191,729 - $443,246
206,161 Added 106.09%
400,493 $560,000
Q3 2023

Nov 13, 2023

BUY
$2.33 - $5.07 $12,001 - $26,115
5,151 Added 2.72%
194,332 $462,000
Q2 2023

Aug 10, 2023

BUY
$4.67 - $6.55 $878,609 - $1.23 Million
188,139 Added 18055.57%
189,181 $906,000
Q1 2023

May 12, 2023

SELL
$4.95 - $6.09 $1,485 - $1,827
-300 Reduced 22.35%
1,042 $5,000
Q4 2022

Feb 10, 2023

SELL
$5.09 - $9.05 $16,496 - $29,331
-3,241 Reduced 70.72%
1,342 $7,000
Q3 2022

Nov 14, 2022

BUY
$3.5 - $7.2 $12,393 - $25,495
3,541 Added 339.83%
4,583 $29,000
Q2 2022

Aug 10, 2022

BUY
$2.7 - $7.62 $135 - $381
50 Added 5.04%
1,042 $3,000
Q1 2022

May 04, 2022

BUY
$6.3 - $8.84 $18 - $26
3 Added 0.3%
992 $7,000
Q3 2021

Nov 05, 2021

SELL
$5.46 - $22.6 $3,210 - $13,288
-588 Reduced 37.29%
989 $7,000
Q2 2021

Aug 02, 2021

BUY
$18.46 - $24.36 $295 - $389
16 Added 1.02%
1,577 $38,000
Q1 2021

May 13, 2021

BUY
$17.66 - $28.92 $14,816 - $24,263
839 Added 116.2%
1,561 $32,000
Q4 2020

Feb 10, 2021

SELL
$23.25 - $37.73 $3,417 - $5,546
-147 Reduced 16.92%
722 $17,000
Q3 2020

Nov 12, 2020

SELL
$3.74 - $28.74 $36,393 - $279,668
-9,731 Reduced 91.8%
869 $24,000
Q1 2020

May 18, 2020

BUY
$2.64 - $3.82 $27,984 - $40,492
10,600 New
10,600 $38,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.